RecruitingNCT05980949
About this title
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Read the official source — NCT05980949Official study titleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
In FranceSchizophreniaMedication studyAges 55–90
- Countries
- France, United States, Canada, + 27 others
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
RecruitingNCT07129928
About this title
Organizational Strategies and Psychosocial Skills for Maintaining Physical Activity After a Depressive Episode: a 3-month Post-rehabilitation Study.
Read the official source — NCT07129928Official study titleOrganizational Strategies and Psychosocial Skills for Maintaining Physical Activity After a Depressive Episode: a 3-month Post-rehabilitation Study.
In FranceDepressionObservational studyAges 18+
- Countries
- France
- Sponsor
- Hopital La Musse
RecruitingNCT07029581
About this title
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
Read the official source — NCT07029581Official study titleA Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
In FranceSchizophreniaMedication studyAges 55–84
- Countries
- France, United States, Bulgaria, + 3 others
- Sponsor
- ACADIA Pharmaceuticals Inc.